---
title: "Coeptis Therapeutics Holdings, Inc. (COEP.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/COEP.US.md"
symbol: "COEP.US"
name: "Coeptis Therapeutics Holdings, Inc."
industry: "Biotechnology"
---

# Coeptis Therapeutics Holdings, Inc. (COEP.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [coeptistx.com](https://coeptistx.com) |

## Company Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an alloge...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-26T04:30:14.000Z

**Overall: C (0.60)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 146 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -7.55% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 6.92 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 71.74M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 500996.00 |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -163.12% | E |
| Profit Margin | -2472.91% | E |
| Gross Margin | 80.98% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% | C |
| Net Profit YoY | -7.55% | C |
| Total Assets YoY | 58.35% | A |
| Net Assets YoY | 119.11% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -4.04% | D |
| OCF YoY | 0.00% | D |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.04 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 23.02% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Coeptis Therapeutics Holdings, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-163.12%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-2472.91%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "80.98%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-7.55%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "58.35%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "119.11%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-4.04%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.04",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "23.02%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.73 | 385/602 | - | - | - |
| PB | 6.85 | 345/602 | 10.56 | 7.60 | 5.55 |
| PS (TTM) | 141.81 | 262/602 | 510.81 | 265.38 | 157.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2024-06-17T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.33 |

## References

- [Company Overview](https://longbridge.com/en/quote/COEP.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/COEP.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/COEP.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.